The first of two papers coming out from the Movember GAP1 Urine Biomarker Consortium looking at how epigenetics can...

The first of two papers coming out from the Movember GAP1 Urine Biomarker Consortium looking at how epigenetics can be used to identify clinically significant prostate cancer. I contributed some analyses and advice to this one. More exciting stuff coming soon from this project.

Movember Foundation
https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-018-0575-z

Comments

Popular posts from this blog

A census of amplified and overexpressed human cancer genes : Nature Reviews Cancer

RT @jburnmurdoch: Most useful thread I’ve read on the dynamics of Covid transmission. By an expert, and packed full of links to evidence. Indoor spaces and or prolonged face-to-face contact account for large majority of Covid transmission. Walking past someone in street/park much lower risk. https://t.co/fnMrDjAxfq

The Cancer Genetics Team at UEA Norwich have a fully-funded 3 year lab-based PhD studentship that will be examining Liquid Biopsy Analysis for Poor Prognosis Categories of Prostate Cancer. Check it out. Deadline: August 31, 2020. Start Date: Feb 2021. https://t.co/YJYwG7cXKv https://t.co/gQXphhLJy6